Cancer, Fecal Microbiota Transplantation, Immune Checkpoint Inhibitors, Immunotherapy
Conditions
Brief summary
The intestinal microbiome forms a symbiotic relationship with the human host and continuously interacts with its immune system. Specific compositions of the intestinal microbiome in patients with cancer have been linked to the response to therapy with cancer immunotherapies (CI), such as immune checkpoint inhibitors (ICIs). The investigators hypothesize that fecal microbiota transplantation (FMT) from patients being responsive to ICI therapy (FMT-Donor) can modulate the intestinal microbiome of patients with CI-refractory malignancies (FMT-Recipients) and render them into responders. Successful proof-of-concept studies showed that reversion from an ICI non-responsive to a responsive disease is indeed possible in melanoma patients after FMT. This trial expands the FMT intervention to patients with any malignancy treated with cancer immunotherapy as a standard of care, to demonstrate the feasibility of this FMT approach as a novel option in cancer therapy.
Interventions
BIOLOGICALFecal Microbiota Transplantation (FMT)
Single-dose of fecal microbiota from FMT-Donor transplanted endoscopically to FMT-Recipient in between two cycles of CI.
Sponsors
Michael Scharl
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
General inclusion criteria for all participants: * Patients, at minimum 18 years of age, male or female * Signed informed consent obtained from subject according to local regulations * ECOG score at the time of study enrolment 0-1 The investigators will include patients/individuals fulfilling inclusion criteria for one of the following groups: 1. Patients with refractory malignancy (FMT-Recipients). The investigators will recruit 25 individuals with stable or progressing disease after minimum of 1 cycle of CI. 2. Patients with malignancy in remission after ICI therapy (FMT-Donors). The investigators will recruit 5 patients willing to donate stool samples for the study. Inclusion criteria FMT-Recipients: 1. Histologically or cytologically confirmed diagnosis of malignancy 2. Currently treated with CI with at least 1 cycle completed. Multiple active malignancies are allowed. 3. Patient with stable or progressive disease as shown at the most recent staging method and decided by the treating investigator (based on the radiologic assessment). 4. Must be CI refractory/resistant as judged by the treating physician based on a recent CT or PET-CT (PET-MRI) scan not older than 8 weeks before screening visit. 5. Willingness to receive FMT administered via colonoscopy and undergo necessary bowel preparation pre-procedure. 6. Demonstrate adequate organ function as defined below, all screening labs should be performed within 28 days of FMT intervention. Following laboratory parameters need to be met: * Platelet count ≥ 50 x 10\^9 / L * Hemoglobin ≥ 8.5 g/dL * Prothrombin time (PT)-international normalized ration (INR) ≤ 1.5 7. Female subject of childbearing potential should have a negative urine pregnancy within minimum 8 hours prior to receiving the study intervention (FMT). If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. 8. Female subjects of childbearing potential must be willing to use a clinically established method of contraception before the FMT procedure. Inclusion criteria FMT-Donors: 1. Documented history of malignancy treated with ICI therapy. 2. Featuring partial or complete response of the malignancy as assessed by radiologic examination with a minimum duration of remission lasting ≥12 months measured since initiation of therapy. 3. Willingness to complete donor-specific questionnaire. 4. Willingness to complete donor-specific serologic and stool testing to evaluate infectious agents. 5. Patient tested negatively for all infectious agents specified. 6. Willingness to provide multiple stool samples, until total amount reaches 170g. 7. Absence of major gastrointestinal symptoms 3 months prior to stool donation (including frequent vomiting, diarrhea, bleeding, constipation).
Exclusion criteria
FMT Recipients: 1. Presence of absolute contra-indications to colonoscopy and/or FMT administration: * Toxic megacolon * Inflammatory bowel disease * Anatomic contra-indications to colonoscopy * Colectomy 2. Patient is currently participating and receiving other study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of this study intervention. 3. Currently under any form of systemic antibiotics. 4. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (\> 10 mg prednisone daily or equivalent) or any other form of immunosuppressive therapy two weeks prior to trial treatment. Patients receiving systemic steroids at physiologic doses are permitted to enroll assuming steroid dose is not above the acceptable threshold (\> 10 mg prednisone daily or equivalent). 5. Severe anaphylactic reaction to any food (food allergies). 6. Had a severe hypersensitivity reaction to propofol. 7. Has serious concomitant illnesses. The eligibility can be granted by the treating investigator on individual bases. 8. Has HIV infection or AIDS-related illness. 9. Has active infection of HAV, HBV or HCV. Patients with a history of Hepatitis B/C infection who have received anti-viral therapy and are disease free may be considered for enrollment after discussion with Principal Investigator. 10. Patient has received a live vaccine within 4 weeks prior to the first dose of treatment. Seasonal influenza vaccines or COVID-19 vaccines for injection are generally inactivated virus vaccines and are allowed. 11. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. 12. Females who are pregnant or breastfeeding. 13. Active central nervous system (CNS) metastases and/or leptomeningeal involvement.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in the intestinal microbiome community | up to 24 weeks | Mean change from baseline of bacterial species compared with 24 weeks post fecal microbiota transplantation (FMT). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate | up to 24 weeks | Percentage of participants that achieved an objective response as per Response Evaluation Criteria in Solid Tumours (iRECIST) treated with immunotherapy. |
| Progression-Free Survival | up to 24 weeks | Time, measured in days, between the fecal microbiota transplantation (FMT) and disease progression as per Response Evaluation Criteria in Solid Tumours (iRECIST) treated with immunotherapy. |
| Overall Survival | up to 24 weeks | The length of time (in days) from study intervention that participants remain alive. |
| Adverse Events Related to Study Intervention | up to 24 weeks | Number of adverse events and serious adverse events related definitely to fecal microbiota transplantation (FMT). |
| CI response rate upon microbiome change | up to 24 weeks | Number of participants with specific bacteria species that positively correlate with the favorable response to cancer immunotherapy. |
| Quality of life based on the questionnaire | up to 24 weeks | Scoring based on European Organization for Research and Treatment of Cancer 30-item quality of life questionnaire (EORTC QLQ C-30). |
| Correlation between specific immune cell presence in blood/colon tissue and therapy response | up to 24 weeks | Number of immune cells in peripheral blood, intestinal and tumor tissue at the time of stool donation, baseline and after 24 weeks post fecal microbiota transplantation (FMT). |
Countries
Switzerland
Outcome results
None listed